Global Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 88.9 Million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on better treatment approaches either by introducing new drugs or by improving existing therapies for the treatment of Alagille syndrome. Some companies are also exploring gene therapy as a potential treatment option. These advancements in treatment options for alagille syndrome are driven by the growing understanding of the underlying genetic causes of the disease. Additionally, clinical trials are being conducted to evaluate the safety and efficacy of these new approaches, offering hope for improved outcomes for patients with Alagille syndrome. Furthermore, researchers are investigating the use of stem cell therapy as a potential treatment for Alagille syndrome. This approach involves replacing damaged or missing liver cells with healthy ones derived from stem cells, offering a promising avenue for long-term disease management. Additionally, efforts are being made to enhance early detection methods for Alagille syndrome, allowing for timely intervention and improved patient outcomes.
Global Alagille Syndrome Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.
Global Alagille Syndrome Treatment Market: Key Developments
On June 14, 2023, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that data from LIVMARLI (maralixibat) oral solution clinical studies evaluating patients with Alagille syndrome (ALGS) were published in Hepatology. LIVMARLI is the first and only approved treatment for cholestatic pruritus in patients with Alagille syndrome three months of age and older. The overall findings from the retrospective analysis suggests that patients with ALGS treated with LIVMARLI who meet the identified prognostic parameters may have improved six-year survival and clinical outcomes. In the analysis, 46 pre-specified variables were evaluated as potential predictors of event-free and transplant-free survival (EFS and TFS) from the LIVMARLI ALGS clinical program. Patients were assessed for up to six years; EFS was defined as absence of Liver Transplant (LT), Surgical Biliary Diversion (SBD), hepatic decompensation, or death; TFS was absence of LT or death.
Browse 26 Market Data Tables and 28 Figures spread through 156 Pages and in-depth TOC on “Global Alagille Syndrome Treatment Market”- Forecast to 2030, Global Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Alagille Syndrome Treatment Market:
- The global alagille syndrome treatment market is expected to exhibit a CAGR of 6% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global alagille syndrome treatment market.
- Among drug, the ursodeoxycholic acid segment is expected to hold a dominant position in the global alagille syndrome treatment market during the forecast period, and this is attributed to the increasing use of ursodeoxycholic acid for the development of drugs for alagille syndrome treatment.
- Among region, North America is expected to be the dominant region in the global alagille syndrome treatment market due to the increasing prevalence rate of Alagille syndrome in the U.S.
- The major players operating in the global alagille syndrome treatment market are Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Ipsen Pharma, and CANbridge Pharmaceuticals, Inc.